Monday, August 11, 2014

Facts: SOME POSITIVE TRIALS! (from ASCO)

*Multicenter phase II trial in RECURRENT Ovarian Cancer
Cediranib 30 mg daily + Olaprib 200mg PO BID   Vs   Olaparib 400 mg BID
POSITIVE TRIAL, EVEN IN PATIENT WITHOUT BRCA MUTATION!
and quite a big difference   PFS   17 months Vs 9 months

*In Head and neck,  Cisplatin-RT  is king for treatment
BUT ADD CETUXIMAB IN KRAS variant group

*In Medullary Thyroid cancer
Vandetanib Objective response 45%
30 months PFS   Vs  Placebo 19 months
-RET Mutation in FAMILIAL or HEREDITARY Medullary Thyroid cancer

also effective Motezanil, Cabozantinib, Sorafenib, Axitinib  (MOUTH FULL!!!!)

*IODINE THERAPY FOR METASTATIC THYROID CANCER
RR 70%
for those refractory to Iodine RT
1.  Chemotherapy   gives Median survival 5 months
2.  Lenvatinib 24 mg PO daily  OR 65%
and PFS 18.3 months  (read up on side effects)

Nexavar, an option in this disease!

*MPDL3280A, by inhibiting PD-L1, will have significant activity in Metastatic Urothelial Bladder cancer.
Post a Comment